Biopharma | December 16, 2025
FDA accepts Sentynl Therapeutics CUTX-101 NDA resubmission
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
Clinical trial enrollment has long been a bottleneck in drug development
Ryght AI tackles these hurdles with its AI Site Twin platform
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
The innovation -- UPM Circular Renewable Black -- is the world’s first bio-based, near-infrared (NIR) detectable, carbon-negative black
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
GSK holds exclusive global rights (excluding mainland China, Hong Kong, Macau, and Taiwan) from Hansoh Pharma to advance its development and commercialization
The new centre brings advanced corneal procedures pioneered in India
Subscribe To Our Newsletter & Stay Updated
